Vaccine watch: Promising developments from one trial

Moderna releases promising data from early trials, while additional research suggests COVID-19 antibodies may fade over time.
2:55 | 07/16/20

Coming up in the next {{countdown}} {{countdownlbl}}

Coming up next:

{{nextVideo.title}}

{{nextVideo.description}}

Skip to this video now

Now Playing:

{{currentVideo.title}}

Comments
Related Extras
Related Videos
Video Transcript
Transcript for Vaccine watch: Promising developments from one trial
Reopening schools and businesses safely will of course with a much easier to manage once there's a safe vaccine. And there have been surprising developments on that front this week is our Bob Woodruff explains. Another landmark week in the race for a vaccine. One of the companies leading the charge maternal just released what they say is promising data from their phase one human trials. This is the World Health Organization says there are now 23 vaccines. That have advanced to human trials. What we've learned from these phase one data are a number of things first we've demonstrated that we have a vaccine that can educate the immune system to generate the right kind of been in an immune response that is neutralizing antibodies. The reason that's important is because that's the kind of an Indian response than any vaccine is shooting for. McDermott claims this new data has shown their vaccine is safe but noted mild side effects can. There are her movie when you get shot and you may experience and flu like symptoms that are generally mild to moderate in nature. Transient intimate as flu like symptoms you can get bad penny you can get cheaper you can feel someone who thinks I'm Marcus is gone the next they're so. And if that's what you'd have to experience in order to ensure you are immune system can recognize this virus be it from Kobe ninety. Net benefit be worth it. Research out of the UK suggests that antibodies caused by the infection may fade over time. A potential wrinkle in vaccine development. You hear people talk about these neutralizing antibodies and it's something that is still an emerging area of science when we did in fact. Our body's immune system generates these antibodies have the ability. Block Burris from and so. Though research is ongoing experts say any vaccine could require an additional shot sometime after the initial vaccination. So you can ask for your games your vaccine still going to be protected here at the entrance. With the current rate of infection and what EC and the community is right now cross country. That would be a tremendous step for a which. McDermott is vaccine is on track to enter the next stage of human trials along with some of its competitors. However but turn a says the world needs more than one success story. I only have two competitors in this race. Car but. We need every vaccine that can make it across the finish line to succeed here because not a single company has the answer on their own in terms of capacity over that's needed. To achieve what humanity is facing right now. Madonna hopes its vaccine will be ready for emergency use by the fall. This is Bob Woodruff tracking the race for a vaccine.

This transcript has been automatically generated and may not be 100% accurate.

{"duration":"2:55","description":"Moderna releases promising data from early trials, while additional research suggests COVID-19 antibodies may fade over time.","mediaType":"default","section":"ABCNews/Health","id":"71810487","title":"Vaccine watch: Promising developments from one trial","url":"/Health/video/vaccine-watch-promising-developments-trial-71810487"}